MedPath

The effect of a specialized physiotherapy program in female patients with systemic sclerosis and inflammatory muscle disorders

Not Applicable
Completed
Conditions
Systemic sclerosis/scleroderma, idiopathic inflammatory myopathies/myositis
Musculoskeletal Diseases
Systemic sclerosis, Myositis
Registration Number
ISRCTN91200867
Lead Sponsor
Revmatologický Ústav
Brief Summary

2023 Results article in https://pubmed.ncbi.nlm.nih.gov/37221419/ results (added 24/05/2023)

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Female
Target Recruitment
12
Inclusion Criteria

1. An Independent Ethics Committee approved written Informed Consent form is signed and dated by the subject
2. Subject is considered reliable and capable of adhering to the protocol and visit schedule
3. Subject is female at least 18 years of age
4. Subject fulfilled the 2013 EULAR/ACR classification criteria for systemic sclerosis or Bohan/Peter 1975 criteria for polymyositis/dermatomyositis
6. Subject is regularly followed at our out-patient department and adheres to the standard-of-care pharmacological therapy indicated by his treating rheumatologist
7. Subject is willing to participate in the study and undergo all planned examinations
8. Subject reported low sexual function at least in two of three questionnaires assessing sexual function: Female Sexual Function Index (FSFI), Brief Index of Sexual Functioning for Women (BISF-W), Sexual Function Questionnaire (SFQ-28). Low sexual function in FSFI and SFQ-28 was established based on diagnostic cut-off scores, and in BISF-W, sexual dysfunction was determined based on the 15th percentile obtained from a comparison of healthy control scores of the same age

Exclusion Criteria

1. Subject has any other condition, including medical or psychiatric, which in the investigator's judgment would make the subject unsuitable for inclusion in the study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<br> Measured at baseline and week 8:<br> 1. Sexual function assessed with the Female Sexual Function Index questionnaire (FSFI) and the Brief Index of Sexual Functioning for Women questionnaire (BISF-W)<br> 2. Quality of sexual life assessed by Sexual Quality of Life – Female questionnaire (SQoL-F)<br>
Secondary Outcome Measures
NameTimeMethod
<br> Measured at baseline and week 8:<br> 1. Health/disability assessed by Health Assessment Questionnaire questionnaire (HAQ)<br> 2. Quality of life assessed by Medical Outcomes Short Form-36 questionnaire (SF-36)<br> 3. Depression assessed by Beck's Depression Inventory-II questionnaire (BDI II)<br>
© Copyright 2025. All Rights Reserved by MedPath